Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world study
IntroductionThe MET exon 14 skipping (METex14) mutation is an important oncogenic driver in lung cancer. We performed a retrospective analysis of clinical data from lung cancer patients with the METex14 mutation to analyze their survival outcomes and associated prognostic factors.MethodsA one-step r...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1113696/full |
| _version_ | 1811157719313285120 |
|---|---|
| author | Chien-Hung Gow Chien-Hung Gow Chien-Hung Gow Min-Shu Hsieh Yi-Lin Chen Yi-Nan Liu Shang-Gin Wu Shang-Gin Wu Jin-Yuan Shih Jin-Yuan Shih |
| author_facet | Chien-Hung Gow Chien-Hung Gow Chien-Hung Gow Min-Shu Hsieh Yi-Lin Chen Yi-Nan Liu Shang-Gin Wu Shang-Gin Wu Jin-Yuan Shih Jin-Yuan Shih |
| author_sort | Chien-Hung Gow |
| collection | DOAJ |
| description | IntroductionThe MET exon 14 skipping (METex14) mutation is an important oncogenic driver in lung cancer. We performed a retrospective analysis of clinical data from lung cancer patients with the METex14 mutation to analyze their survival outcomes and associated prognostic factors.MethodsA one-step reverse transcription-polymerase chain reaction to examine the presence of the METex14 mutation was performed using RNA samples from 1374 lung cancer patients with no detected EGFR and ALK mutations. Pathological features and immunohistochemistry (IHC) results for c-MET were analyzed in patients with METex14-positive tumors.ResultsMETex14 was identified in 69 patients with lung cancer, including 53 adenocarcinoma (ADC) and 16 non-ADC patients. In comparison with patients without the METex14 mutation, lung cancer patients harboring the METex14 mutation were generally elderly individuals, never-smokers, and had poor performance scores. A higher frequency of METex14 mutations was detected in pulmonary sarcomatoid carcinoma (PSC) patients (24.3%, n = 9/37). However, stage IV PSC patients with or without the METex14 mutations showed similarly poor overall survival (OS) (p = 0.429). For all 36 METex14-positive lung ADCs, multivariate analysis showed several poor prognostic factors, including strong c-MET IHC staining (p = 0.006), initial brain metastasis (p = 0.005), and administration of only supportive care (p < 0.001). After excluding seven patients who received only supportive care, we further analyzed 29 stage IV lung ADC patients with METex14 mutations who received anti-cancer treatment. Multivariate analysis showed that pemetrexed treatment (p = 0.003), lung radiotherapy (p = 0.020), initial brain metastasis (p = 0.005), and strong c-MET IHC staining (p = 0.012) were independent prognostic factors for OS in these patients.ConclusionsA higher frequency of METex14 mutations was detected in PSC patients. Stage IV PSC patients with or without the METex14 mutations had similarly poor overall survival. Pemetrexed-based chemotherapy, strong c-MET ICH staining, initial brain metastasis, and lung radiotherapy, may help predict survival outcomes in patients with advanced lung ADCs harboring the METex14 mutation. |
| first_indexed | 2024-04-10T05:12:05Z |
| format | Article |
| id | doaj.art-dda4673d0b774d658acbb8530f02b849 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T05:12:05Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-dda4673d0b774d658acbb8530f02b8492023-03-09T07:12:39ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-03-011310.3389/fonc.2023.11136961113696Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world studyChien-Hung Gow0Chien-Hung Gow1Chien-Hung Gow2Min-Shu Hsieh3Yi-Lin Chen4Yi-Nan Liu5Shang-Gin Wu6Shang-Gin Wu7Jin-Yuan Shih8Jin-Yuan Shih9Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, TaiwanDepartment of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, TaiwanDepartment of Healthcare Information and Management, Ming-Chuan University, Taoyuan, TaiwanDepartment of Pathology, National Taiwan University Hospital, Taipei, TaiwanDepartment of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, TaiwanDepartment of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, TaiwanDepartment of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, TaiwanDepartment of Internal Medicine, National Taiwan University Cancer Center, National Taiwan University, Taipei, TaiwanDepartment of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, TaiwanGraduate Institute of Clinical Medicine, National Taiwan University, Taipei, TaiwanIntroductionThe MET exon 14 skipping (METex14) mutation is an important oncogenic driver in lung cancer. We performed a retrospective analysis of clinical data from lung cancer patients with the METex14 mutation to analyze their survival outcomes and associated prognostic factors.MethodsA one-step reverse transcription-polymerase chain reaction to examine the presence of the METex14 mutation was performed using RNA samples from 1374 lung cancer patients with no detected EGFR and ALK mutations. Pathological features and immunohistochemistry (IHC) results for c-MET were analyzed in patients with METex14-positive tumors.ResultsMETex14 was identified in 69 patients with lung cancer, including 53 adenocarcinoma (ADC) and 16 non-ADC patients. In comparison with patients without the METex14 mutation, lung cancer patients harboring the METex14 mutation were generally elderly individuals, never-smokers, and had poor performance scores. A higher frequency of METex14 mutations was detected in pulmonary sarcomatoid carcinoma (PSC) patients (24.3%, n = 9/37). However, stage IV PSC patients with or without the METex14 mutations showed similarly poor overall survival (OS) (p = 0.429). For all 36 METex14-positive lung ADCs, multivariate analysis showed several poor prognostic factors, including strong c-MET IHC staining (p = 0.006), initial brain metastasis (p = 0.005), and administration of only supportive care (p < 0.001). After excluding seven patients who received only supportive care, we further analyzed 29 stage IV lung ADC patients with METex14 mutations who received anti-cancer treatment. Multivariate analysis showed that pemetrexed treatment (p = 0.003), lung radiotherapy (p = 0.020), initial brain metastasis (p = 0.005), and strong c-MET IHC staining (p = 0.012) were independent prognostic factors for OS in these patients.ConclusionsA higher frequency of METex14 mutations was detected in PSC patients. Stage IV PSC patients with or without the METex14 mutations had similarly poor overall survival. Pemetrexed-based chemotherapy, strong c-MET ICH staining, initial brain metastasis, and lung radiotherapy, may help predict survival outcomes in patients with advanced lung ADCs harboring the METex14 mutation.https://www.frontiersin.org/articles/10.3389/fonc.2023.1113696/fulladenocarcinomaimmunohistochemistryMET exon 14 skippingpulmonary sarcomatoid carcinomaoverall survival |
| spellingShingle | Chien-Hung Gow Chien-Hung Gow Chien-Hung Gow Min-Shu Hsieh Yi-Lin Chen Yi-Nan Liu Shang-Gin Wu Shang-Gin Wu Jin-Yuan Shih Jin-Yuan Shih Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world study Frontiers in Oncology adenocarcinoma immunohistochemistry MET exon 14 skipping pulmonary sarcomatoid carcinoma overall survival |
| title | Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world study |
| title_full | Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world study |
| title_fullStr | Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world study |
| title_full_unstemmed | Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world study |
| title_short | Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world study |
| title_sort | survival outcomes and prognostic factors of lung cancer patients with the met exon 14 skipping mutation a single center real world study |
| topic | adenocarcinoma immunohistochemistry MET exon 14 skipping pulmonary sarcomatoid carcinoma overall survival |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1113696/full |
| work_keys_str_mv | AT chienhunggow survivaloutcomesandprognosticfactorsoflungcancerpatientswiththemetexon14skippingmutationasinglecenterrealworldstudy AT chienhunggow survivaloutcomesandprognosticfactorsoflungcancerpatientswiththemetexon14skippingmutationasinglecenterrealworldstudy AT chienhunggow survivaloutcomesandprognosticfactorsoflungcancerpatientswiththemetexon14skippingmutationasinglecenterrealworldstudy AT minshuhsieh survivaloutcomesandprognosticfactorsoflungcancerpatientswiththemetexon14skippingmutationasinglecenterrealworldstudy AT yilinchen survivaloutcomesandprognosticfactorsoflungcancerpatientswiththemetexon14skippingmutationasinglecenterrealworldstudy AT yinanliu survivaloutcomesandprognosticfactorsoflungcancerpatientswiththemetexon14skippingmutationasinglecenterrealworldstudy AT shangginwu survivaloutcomesandprognosticfactorsoflungcancerpatientswiththemetexon14skippingmutationasinglecenterrealworldstudy AT shangginwu survivaloutcomesandprognosticfactorsoflungcancerpatientswiththemetexon14skippingmutationasinglecenterrealworldstudy AT jinyuanshih survivaloutcomesandprognosticfactorsoflungcancerpatientswiththemetexon14skippingmutationasinglecenterrealworldstudy AT jinyuanshih survivaloutcomesandprognosticfactorsoflungcancerpatientswiththemetexon14skippingmutationasinglecenterrealworldstudy |